Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib PK and Toxicity in Ovarian Cancer
NCT04861181Phase 4Terminated
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of niraparib in ovarian cancer, sponsored by Hospices Civils de Lyon. Primary endpoint: Identification of metrics (clinical, biological, pharmacokinetic) that are considered as toxicity induction causes (hematological toxicity or nephrotoxicity) at Month 10. Started May 2021; status: terminated.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04861181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861181.